

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jenscare Scientific Co., Ltd.**  
**寧波健世科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 9877)**

**VOLUNTARY ANNOUNCEMENT**

**KEN-VALVE OBTAINED REGISTRATION APPROVAL FROM NMPA  
AND ACTIVE PROGRESSION OF COMMERCIALIZATION**

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated data in relation to the latest business and new product development of the Group.

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that recently, Ken-Valve, a TAVR product, one of the Company’s core products, has obtained registration approval from the National Medical Products Administration, the medical device production permit and the national medical insurance code. The Company is actively progressing the work relating to the commercialization of Ken-Valve.

Ken-Valve is a relatively rare TAVR product for the treatment of aortic regurgitation (or combined with aortic stenosis) in the market. Ken-Valve features a multi-size design with advantage on allowing for a larger anchoring area, which is expected to accommodate a broad range of patient populations. The Ken-Valve’s integrated positioning anchor design provides stable and reliable anchoring force, and the design of sealing skirt is expected to effectively reduce the incidence of paravalvular leakage post procedure. The design of delivery system with steerable functions is expected to shorten the learning curve for physicians, producing better procedural results.

The Company will adopt various measures to take advantage of this market opportunity to continuously expand the coverage of sales networks and targeted customers. Meanwhile, the Company will keep optimizing production costs and operating efficiency to achieve its revenue target.

**Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** There is no assurance that the Company will ultimately develop, market and/or commercialize Ken-Valve successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board  
**Jenscare Scientific Co., Ltd.**  
**Mr. PAN Fei**

*Executive Director and Chief Executive Officer*

Hong Kong, March 25, 2025

*As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.*